Expanded access programs regulation

Introduction

Expanded Access Programs (EAPs), also known as compassionate use programmes, allow patients suffering from serious or life-threatening diseases to access investigational medicines that have not yet received marketing approval. These programmes are particularly important when patients have exhausted available treatment options or cannot participate in clinical trials.

In biotechnology and pharmaceutical research, new medicines may require several years of clinical testing before receiving regulatory approval. However, some patients cannot wait until the completion of the entire approval process. Expanded access programmes provide a regulated mechanism through which investigational drugs, biological products and other experimental treatments may be made available to eligible patients.

The main objective is to balance patient welfare, medical necessity, scientific integrity and regulatory safety.

Meaning and Objectives of Expanded Access Programs

Expanded access refers to the use of an investigational medical product outside a clinical trial, subject to regulatory permission and other applicable conditions.

These programmes are generally intended for patients who:

Have a serious or immediately life-threatening disease.

Have no satisfactory approved treatment options.

Are unable to participate in an appropriate clinical trial.

May reasonably benefit from the investigational treatment.

Have received adequate information about potential risks and uncertainties.

Expanded access is not equivalent to ordinary marketing approval. An investigational product remains unapproved, and its safety and effectiveness may not yet be fully established.

Types of Expanded Access Programs

1. Individual Patient Access

This programme allows an individual patient to receive an investigational medicine when the treating physician believes that access may be medically justified.

In the United States, the Food and Drug Administration (FDA) permits individual-patient expanded access under 21 CFR 312.310, subject to applicable conditions.

2. Intermediate-Size Patient Population Access

This category concerns access for a group of patients who are not sufficiently large to justify a clinical trial but may benefit from an investigational treatment.

Under the US framework, 21 CFR 312.315 governs intermediate-size patient populations.

3. Widespread Treatment Use

This category allows investigational products to be made available to larger patient populations in specified circumstances.

Under the US framework, 21 CFR 312.320 governs treatment use involving widespread access.

4. Emergency Expanded Access

Emergency access may be considered where a patient requires urgent treatment and there is insufficient time to complete ordinary regulatory procedures.

However, emergency access does not eliminate the need for appropriate medical supervision, reporting and subsequent regulatory compliance.

Regulatory Framework in India

India does not currently have a single comprehensive regulatory programme identical to the US FDA's expanded access framework. However, investigational medicines may be made available through relevant provisions of the New Drugs and Clinical Trials Rules, 2019 (NDCTR) and other applicable requirements.

The regulatory framework includes the following:

1. Drugs and Cosmetics Act, 1940

This Act provides the principal statutory foundation for regulating the import, manufacture, distribution and sale of drugs in India.

2. New Drugs and Clinical Trials Rules, 2019

These rules regulate clinical trials and other specified activities involving new drugs. They establish requirements concerning permissions, ethics committee oversight, informed consent and participant protection.

Rule 33 is particularly relevant to clinical trial permissions, while the applicable provisions concerning ethics committee approval and informed consent must also be considered.

3. Central Drugs Standard Control Organisation (CDSCO)

CDSCO, under the Ministry of Health and Family Welfare, performs important regulatory functions concerning new drugs and clinical trials.

4. Institutional Ethics Committees

Ethics committees examine whether proposed access arrangements adequately protect patients, respect informed consent and maintain appropriate medical oversight.

5. ICMR National Ethical Guidelines

The Indian Council of Medical Research's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, provide important ethical standards for biomedical research. These guidelines are not an Act of Parliament but are influential in research governance.

International Regulatory Framework

The United States has one of the most developed expanded access systems.

The FDA regulates expanded access under 21 CFR Part 312, Subpart I. The framework establishes eligibility conditions, physician responsibilities, informed consent requirements and institutional review board oversight.

The European Union regulates compassionate use under Article 83 of Regulation (EC) No. 726/2004. It permits member states to make certain unauthorised medicinal products available to groups of patients suffering from seriously debilitating or life-threatening diseases when satisfactory authorised treatments are unavailable.

The World Health Organization also provides ethical guidance on the use of unregistered and investigational interventions, particularly during public health emergencies.

Ethical and Legal Requirements

1. Informed Consent

Patients must receive understandable information about the investigational treatment, including its experimental status, known risks, possible benefits and available alternatives.

Consent should be voluntary and properly documented according to applicable legal requirements.

2. Medical Necessity

Expanded access should be based on a genuine medical need rather than commercial pressure or personal preference.

3. Safety Monitoring

Physicians and sponsors must follow applicable safety-monitoring and adverse-event reporting requirements.

4. Regulatory and Ethics Approval

Access must comply with the relevant regulatory pathway and ethics oversight requirements. Approval in one jurisdiction does not automatically authorise access in another.

5. Fair Patient Selection

Selection criteria should be medically justified, transparent and non-discriminatory. Companies and healthcare institutions should avoid arbitrary allocation of limited investigational products.

Important Case Laws

Direct Indian judicial decisions specifically interpreting expanded access programmes are limited. Nevertheless, several important judgments establish principles relevant to compassionate access, patient autonomy and investigational medical treatment.

1. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court examined the principles of informed consent in medical treatment. It held that valid consent must be voluntary and based on adequate information about the proposed procedure.

The judgment is relevant to expanded access because patients receiving investigational medicines must understand the experimental nature of treatment and its possible consequences.

2. Common Cause v. Union of India (2018)

The Supreme Court recognised the importance of individual autonomy and dignity in medical decision-making, particularly concerning end-of-life care.

Although the case did not concern investigational medicines, its constitutional reasoning supports respect for patient autonomy in medical treatment decisions.

3. Suchita Srivastava v. Chandigarh Administration (2009)

The Supreme Court recognised reproductive autonomy as an important aspect of personal liberty under Article 21.

The judgment is relevant to the broader principle that medical decisions involving individuals must respect personal autonomy and informed choice.

4. Devika Biswas v. Union of India (2016)

The Supreme Court examined serious deficiencies in sterilisation procedures and emphasised the importance of informed consent, medical standards and protection of patient dignity.

The decision is relevant to expanded access because experimental treatment must not compromise patient safety or informed decision-making.

5. Jacob Mathew v. State of Punjab (2005)

The Supreme Court clarified important principles concerning medical negligence and professional responsibility.

The judgment is relevant to expanded access because treating physicians must exercise appropriate professional care when administering investigational treatments.

Challenges in Expanded Access Regulation

Expanded access programmes involve several legal and ethical difficulties.

First, investigational medicines may have incomplete safety information. Therefore, patients may face uncertain risks despite having serious medical conditions.

Second, limited product availability can create difficult decisions concerning patient selection and fairness.

Third, expanded access may create tension between individual patient needs and the scientific requirements of clinical trials.

Other important challenges include:

Delays in regulatory permissions.

Unclear responsibilities between sponsors and treating physicians.

Difficulties in obtaining informed consent.

Unequal access based on geographical and financial circumstances.

Confidentiality of patient medical information.

Long-term safety monitoring.

Uncertainty concerning treatment costs and product supply.

Conclusion

Expanded Access Programs provide an important legal and ethical mechanism for making investigational medicines available to patients with serious medical conditions when satisfactory treatment alternatives are unavailable.

International frameworks, particularly the US FDA regulations under 21 CFR Part 312 and Article 83 of EU Regulation 726/2004, establish structured approaches to compassionate access. In India, the Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019 and relevant ethical guidelines provide the regulatory foundation for related activities, although India does not have an identical standalone expanded access system.

Judgments such as Samira Kohli v. Dr. Prabha Manchanda and Devika Biswas v. Union of India reinforce the importance of informed consent, medical safety and patient dignity. Ultimately, expanded access regulation must balance urgent patient needs with scientific responsibility, transparent decision-making and effective regulatory supervision.